Research chemicalStimulantResearch chemicalSubstituted methamphetamine

2-Fluoromethamphetamine (2-FMA)

Also known as 2-FMA · ortho-fluoromethamphetamine

Written by enwyReviewed 4 Aug 20262 sources0 comments

2-Fluoromethamphetamine (2-FMA) is a fluorinated methamphetamine analogue used as a functional stimulant. Users describe a clear-headed, focused profile with relatively low euphoria, which has made it a popular 'productivity' research chemical. Human data is limited to anecdote and analytical reports.

01 Overview

2-FMA is a ring-fluorinated analogue of methamphetamine. It is often described by users as a relatively clean, functional stimulant with strong focus and wakefulness but comparatively modest euphoria, making it one of the more widely used designer stimulants for cognitive/wakefulness purposes.

There are no controlled human trials. Its reputation for functionality does not remove class hazards: cardiovascular strain, sleep disruption, comedown and dependence remain concerns, and its long-term and neurotoxic effects are unknown.

02 Mechanism

Acts as a releasing agent and reuptake inhibitor of dopamine and noradrenaline, similar to methamphetamine but with a subjectively less euphoric, more functional profile attributed to the ortho-fluoro substitution.

03 Dosing

Tier	Dose	Route	Notes
Light	10–25 mg	Oral	Anecdotal functional dose range.
Common	10–30 mg	Insufflated	Faster onset; increases redosing and cardiovascular risk.
Common	25–50 mg	Oral	Duration commonly reported 5-8 hours.

04 Effects

Effect	Magnitude	Evidence
Focus and wakefulnessClear-headed stimulation and sustained attention are the most commonly reported effects.	moderate-strong	Anecdotal
Increased energy and motivationPhysical and mental drive without strong intoxication at moderate doses.		Anecdotal
Appetite suppressionReduced hunger during the active period.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Cardiovascular strainElevated heart rate and blood pressure; higher or insufflated doses increase risk of palpitations and chest discomfort.	Moderate	Common	Unconfirmed
Insomnia and comedownLong half-life causes sleep loss, followed by fatigue, irritability and low mood.	Moderate	Very common	Anecdotal
Compulsive redosing and dependenceThe functional 'productivity' profile encourages daily use, which fosters tolerance and dependence.	Moderate	Common	Anecdotal

06 Legal status

Psychoactive Substances Act 2016

Production and supply prohibited. · as of Jan 2026

United States

Not federally scheduled by name

Possible analogue under the Federal Analogue Act. · as of Jan 2026

07 References

New psychoactive substances overviewEUDA (European Union Drugs Agency)

Analytical characterisation of fluoromethamphetamine isomersPubMed

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.